1887
Volume 2002, Issue 2
  • ISSN: 0253-8253
  • E-ISSN: 2227-0426

Abstract

Current treatment regimens with either long-term interferon (IFN) monotherapy or interferon-ribavirin combination achieve a sustained response of 6-21%. To improve the efficacy of IFN several strategies have been devised, including the use of higher doses of IFN, prolonged courses or pegylated IFN. Some recent reports have suggested that daily administration of IFN in the early phase of therapy (induction dose) may be more efficacious than the classic thrice-weekly regimen. There is no available data about the combination of induction dose regimen of IFN and ribavirin.

Our objective was to evaluate prospectively the efficacy and safety of a 5mu IFN induction dose in combination with ribavirin in HCV patients. End treatment response (ETR) was 36.7% of the 30 patients included in the study, while 81.1% ofresponders could remain viral negative for one year after discontinuation of treatment (sustained response). Though responders had higher pretreatment levels of viraemia and ALT, it was still without statistical signficance. Also, there was no statistical histological difference between both groups. There was a significant correlation between response rate and post induction viraemia level (p < 0.05) but no similar relation to post-induction ALT level. We conclude that induction dose regimen seems to have no effect on ETR but may improve sustained response. Also, post-induction viral load level is a good predictor for both ET and sustained responses.

Loading

Article metrics loading...

/content/journals/10.5339/qmj.2002.2.19
2002-11-01
2019-08-24
Loading full text...

Full text loading...

References

  1. 1. Alter   MJ. . Epidemiology of hepatitis C. . Hepatology . 1997; ;26: suppl : 62– 65 .
    [Google Scholar]
  2. 2. Seeff   LB., , Buskell-Bales   Z., , Wright   EC. , et al. , Long-term mortality after transfusion-associated non-A non-B hepatitis. . N Engl J Med . 1992; ;327: : 1906– 1911 .
    [Google Scholar]
  3. 3. Derby   SC., , Ewart   DW., , Giangrande   PL. , et al. , Mortality from liver cancer and liver disease in haemophilic men and boys given blood product contaminated with hepatitis C. . Lancet . 1997; ;350: : 1425– 1431 .
    [Google Scholar]
  4. 4. Lee   WM. . Therapy of hepatitis c: interferon 2a trials. . Hepatology . 1997; ;26: : 89S– 95S .
    [Google Scholar]
  5. 5. Statement   P. . Management of hepatitis C: N1H consensus development conference panel statement. . Hepatology . 1997; ;26: Supp 10 : 2S– 10S .
    [Google Scholar]
  6. 6. Poynard   T., , Leroy   V., , Cohard   M. , et al. , Meta-analysis of interferon-randomized trials in the treatment of viral hepatitis C: effects of dose and duration. . Hepatology . 1996; ;24: : 778– 789 .
    [Google Scholar]
  7. 7. Reichard   O., , Norkrans   G., , Fry den   An. , et al. , -interferon and ribavirin versus _-interferon alone as therapy for chronic hepatitis C.a randomized, double blind, placebo-controlled study. . Lancet . 1998; ;351: : 83– 87 .
    [Google Scholar]
  8. 8. Lin   R., , Roach   E., , Zimmerman   M. , et al. , Interferon for chronic hepatitis C; effects of dose increment on response rates. . J Hepatology . 1995; ;23: : 487– 496 .
    [Google Scholar]
  9. 9. The Australian hepatitis C study group . Efficacy and tolerance of 6 months course of daily interferon-2a for chronic hepatitis C with cirrhosis. . J viral hepatitis . 1997; ;4: : 317– 323 .
    [Google Scholar]
  10. 10. Lam   NP., , Neumann   AU., , Gretch   DR. , et al. , Dose-dependent acute clearance of hepatitis C genotype I virus with IFN. . Hepatology . 1997; ;26: : 226– 231 .
    [Google Scholar]
  11. 11. Zeuzem   S., , Lee   JH., , Franke   A. , et al. , Quantification of the initial decline of serum hepatitis C virus RNA and response to IFN. . Hepatology . 1998; ;27: : 149– 156 .
    [Google Scholar]
  12. 12. Neumann   AU., , Lam   NP., , Dahari   H. , et al. , Hepatitis C virus dynamics in vivo and the antiviral efficacy of IFN-therapy. . Science . 1998; ;282: : 103– 107 .
    [Google Scholar]
  13. 13. Zeuzam   S., , Schmidt   JM., , Lee   JH. , et al. , Hepatitis C dynamics in vivo: effect of ribavirin and IFN-on viral turnover. . Hepatology . 1998; ;28: : 245– 252 .
    [Google Scholar]
  14. 14. Layden   TJ. . Priciples of IFN induction therapy. . Am J Med . 1999; ;107: : 71S– 73S .
    [Google Scholar]
  15. 15. Gonzales   HJ., , Ho   SB., , Gross   JB. , et al. , High dose induction therapy with IFN is effective in patients with high hepatitis C viral load (Abstract). . Gastroenterology . 1998; ;114: : A1247 .
    [Google Scholar]
  16. 16. Ouzan   D., , Babany   G., , Valla   D. , et al. , Comparison of high initial and fixed-dose regimens of 1FN 2 a in chronic hepatitis C; A randomized controlled trial. . J viral Hepat . 1998; ;5: : 53– 59 .
    [Google Scholar]
  17. 17. Omar   M., , Derbala   MF., , El-Dweik   N. , et al. , Efficacy oflFN therapy for HCV in-patients with Schistosomiasis. Results from a comparative study. . Med J Kasr Al Aini . 1998; ;4: 1 : 247S– 254S .
    [Google Scholar]
  18. 18. Poynard   T., , Daurat   V., , Chevret   S. , et al. , A short induction regimen of IFN-is not effective for treatment of relapse in chronic hepatitis c: a randomized trial. . J Viral Hepat . 1999; ;6: : 381– 386 .
    [Google Scholar]
  19. 19. Chemello   L., , Cavalletto   L., , Bernardinello   E. , et al. , Comparison of thrice weekly Vs daily human leucocyte IFN therapy for chronic hepatitis c: TWH study group. . J Viral Hepat . 1999; ;6: 4 : 321– 327 .
    [Google Scholar]
  20. 20. Bjoro   K., , Bell   H., , Helium   K. , et al. , Randomized trial of IFN induction and ribavirin Vs. standard IFN and ribavirin from chronic hepatitis c in previously untreated patients. . Hepatology . 2000; ;32: suppl : 317 A .
    [Google Scholar]
  21. 21. Carithers   RL., , Zeuzem   S., , Manns   MP. , et al. , Multimember, randomized, controlled trial comparing high dose daily induction IFN plus ribavirin versus standard IFN-2b plus ribavirin. . Hepatology . 2000; ;32: suppl : 317 A .
    [Google Scholar]
  22. 22. Fried   MW., , Shiffman   M., , Sterling   RK. , et al. , multicenter, randomized trial of daily high-dose IFN 2b for the treatment of chronic hepatitis c: pretreatment stratification by viral burden and genotype. . Am J Gastroenterol . 2000; ;95: 1 : 3225– 3229 .
    [Google Scholar]
  23. 23. Fernci   P., , runner   H., , Nachbaur   K. , et al. , Combination of IFN induction therapy and ribavirin in chronic hepatitis c. . Hepatology . 2000; ;34: 5 : 1006– 1011 .
    [Google Scholar]
  24. 24. Nakamura   H., , Ito   H., , Kimura   Y. , et al. , The importance of initial daily administration of IFN for the eradication of hepatitis C virus in patients with chronic hepatitis C: Multicenter randomized trial. . Hepatol-Gastroenterology . 1998; ;45: : 1045– 1055 .
    [Google Scholar]
  25. 25. Brouwer   J., , Hansen   B., , Niesters   H. , et al. , Early prediction of response in IFN mono-therapy and IFN-ribavirin combination therapy for chronic hepatitis C: HCV-RNA at 4 weeks versus ALT. . J Hepatol . 1999; ;30: : 192– 198 .
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/qmj.2002.2.19
Loading
  • Article Type: Research Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error